Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BPMUFNASDAQ:HCMNASDAQ:IMVTNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$47.50$50.45$47.50▼$54.00$625.58M0.4755 shsN/AHCMHUTCHMED$13.40+1.0%$14.27$11.51▼$21.50$2.34B0.55101,429 shs42,598 shsIMVTImmunovant$14.46-0.7%$15.46$12.72▼$34.47$2.46B0.751.22 million shs754,314 shsMLTXMoonLake Immunotherapeutics$38.93+1.1%$38.43$31.42▼$58.26$2.49B1.31353,284 shs133,169 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%0.00%-10.09%-1.35%HCMHUTCHMED0.00%+0.07%-14.87%-16.82%-31.91%IMVTImmunovant0.00%0.00%-4.05%-31.98%-51.08%MLTXMoonLake Immunotherapeutics0.00%+3.48%-1.32%-7.92%-2.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AHCMHUTCHMED2.4506 of 5 stars3.04.00.00.02.00.01.9IMVTImmunovant2.5367 of 5 stars4.51.00.00.03.11.70.0MLTXMoonLake Immunotherapeutics3.1347 of 5 stars4.52.00.00.03.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AHCMHUTCHMED 2.00Hold$19.0041.79% UpsideIMVTImmunovant 2.90Moderate Buy$38.33165.10% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.71102.19% UpsideCurrent Analyst Ratings BreakdownLatest BPMUF, MLTX, IMVT, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.003/19/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.003/10/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.56$1.02 per share46.75($0.94) per share-50.53HCMHUTCHMED$630.20M3.71$0.55 per share24.51$4.27 per share3.14IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.18N/AN/AN/AN/A6/18/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)Latest BPMUF, MLTX, IMVT, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea Pharmaceutica5.704.103.27HCMHUTCHMED0.072.812.68IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/AHCMHUTCHMED8.82%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/AHCMHUTCHMED3.60%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableBPMUF, MLTX, IMVT, and HCM HeadlinesRecent News About These CompaniesWoodline Partners LP Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 24 at 5:01 AM | marketbeat.comNuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 24 at 4:05 AM | marketbeat.comPoint72 Asset Management L.P. Invests $5.35 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 22 at 4:42 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wolfe Research to Outperform RatingMay 21, 2025 | marketbeat.comWexford Capital LP Purchases 10,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21, 2025 | marketbeat.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20, 2025 | msn.comWolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"May 20, 2025 | americanbankingnews.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock NewsMay 19, 2025 | gurufocus.comEnsign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 19, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for MLTX EarningsMay 18, 2025 | americanbankingnews.comPolar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 17, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Purchases 840,731 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $2.94 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lowered by Schonfeld Strategic Advisors LLCMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comWall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a BetMay 15, 2025 | zacks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLCMay 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPMUF, MLTX, IMVT, and HCM Company DescriptionsBasilea Pharmaceutica OTCMKTS:BPMUF$47.50 0.00 (0.00%) As of 05/23/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.HUTCHMED NASDAQ:HCM$13.40 +0.13 (+0.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$13.45 +0.05 (+0.37%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$14.46 -0.10 (-0.69%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.47 +0.01 (+0.07%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$38.93 +0.42 (+1.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$38.98 +0.05 (+0.14%) As of 05/23/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
